Previous articleNext article No AccessMedicaid Drug Formulary RestrictionsDavid DranoveDavid Dranove Search for more articles by this author PDFPDF PLUS Add to favoritesDownload CitationTrack CitationsPermissionsReprints Share onFacebookTwitterLinkedInRedditEmail SectionsMoreDetailsFiguresReferencesCited by The Journal of Law and Economics Volume 32, Number 1Apr., 1989 Sponsored by The University of Chicago Booth School of Business and The University of Chicago Law School Article DOIhttps://doi.org/10.1086/467172 Views: 5Total views on this site Citations: 29Citations are reported from Crossref Copyright 1989 The University of ChicagoPDF download Crossref reports the following articles citing this article:Matthew Grennan, Ashley Swanson Bargaining in Healthcare Markets: Applications of Nash-in-Nash and Extensions, (Apr 2022): 249–270.https://doi.org/10.1007/978-3-030-76666-5_12Giovanni Crea, Matteo M. Galizzi, Ismo Linnosmaa, Marisa Miraldo Physician altruism and moral hazard: (no) Evidence from Finnish national prescriptions data, Journal of Health Economics 65 (May 2019): 153–169.https://doi.org/10.1016/j.jhealeco.2019.03.006W. David Bradford, John L. Turner, Jonathan W. Williams Off‐Label Use Of Pharmaceuticals: A Detection Controlled Estimation Approach, The Journal of Industrial Economics 66, no.44 (Jun 2019): 866–903.https://doi.org/10.1111/joie.12189 Bibliografía, (Jan 2014): 133–140.https://doi.org/10.1016/B978-84-9022-593-6.00021-XDavid Bradford, John L. Turner, Jonathan W. Williams Off-Label Use of Pharmaceuticals: Trends and Drivers, SSRN Electronic Journal (Jan 2013).https://doi.org/10.2139/ssrn.2230976James D. Dana Buyer groups as strategic commitments, Games and Economic Behavior 74, no.22 (Mar 2012): 470–485.https://doi.org/10.1016/j.geb.2011.08.014David Dranove Health Care Markets, Regulators, and Certifiers, (Jan 2011): 639–690.https://doi.org/10.1016/B978-0-444-53592-4.00010-4SARA FISHER ELLISON, CHRISTOPHER M. SNYDER COUNTERVAILING POWER IN WHOLESALE PHARMACEUTICALS, The Journal of Industrial Economics 58, no.11 (Mar 2010): 32–53.https://doi.org/10.1111/j.1467-6451.2010.00408.xKosali Simon, Sharon Tennyson, Julie Hudman Do State Cost Control Policies Reduce Medicaid Prescription Drug Spending?, Risk Management and Insurance Review 12, no.11 (Mar 2009): 39–66.https://doi.org/10.1111/j.1540-6296.2009.01153.xSHARON TENNYSON, HAE KYUNG YANG State Prescription Drug Policies, Cost Barriers, and the Use of Acute Care Services by Medicaid Beneficiaries, Journal of Consumer Affairs 43, no.11 (Feb 2009): 4–25.https://doi.org/10.1111/j.1745-6606.2008.01125.xJames D. Dana Buyer Groups as Strategic Commitments, SSRN Electronic Journal (Jan 2009).https://doi.org/10.2139/ssrn.1504211Sanjoy Roy, S Suresh Madhavan Making a Case for Employing a??Societal Perspective in the Evaluation??of Medicaid Prescription??Drug Interventions, PharmacoEconomics 26, no.44 (Jan 2008): 281–296.https://doi.org/10.2165/00019053-200826040-00002William J. Moore, Etienne E. Pracht Changes in the Effectiveness of State Medicaid Drug Program Cost-Containment Policies Following OBRA 1990, American Journal of Economics and Sociology 66, no.55 (Dec 2007): 901–924.https://doi.org/10.1111/j.1536-7150.2007.00546.xJoan Costa-Font, Panos Kanavos, Joan Rovira Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in Catalonia, Applied Economics 39, no.55 (Mar 2007): 541–551.https://doi.org/10.1080/00036840500438947Haiden A. Huskamp, Richard G. Frank, Kimberly A. McGuigan, Yuting Zhang The Impact of a Three-Tier Formulary on Demand Response for Prescription Drugs, Journal of Economics <html_ent glyph="@amp;" ascii="&"/> Management Strategy 14, no.33 (Sep 2005): 729–753.https://doi.org/10.1111/j.1530-9134.2005.00080.x Prescribing and Prescribing Influence, (Jan 2010): 155–196.https://doi.org/10.1201/9780203010730.ch6Sara Fisher Ellison, Christopher M. Snyder Countervailing Power in Wholesale Pharmaceuticals, SSRN Electronic Journal (Jan 2001).https://doi.org/10.2139/ssrn.277290Douglas Lundin Moral hazard in physician prescription behavior, Journal of Health Economics 19, no.55 (Sep 2000): 639–662.https://doi.org/10.1016/S0167-6296(00)00033-3F.M. Scherer Chapter 25 The pharmaceutical industry, (Jan 2000): 1297–1336.https://doi.org/10.1016/S1574-0064(00)80038-4 Pharmaceutical Pricing at the Change of Millennia, Journal of Pharmaceutical Marketing Practice 1, no.11 (Aug 1997): 99–112.https://doi.org/10.1300/J289V01N01_09Brenda R. Motheral, Kathleen A. Fairman The use of claims databases for outcomes research: rationale, challenges, and strategies, Clinical Therapeutics 19, no.22 (Mar 1997): 346–366.https://doi.org/10.1016/S0149-2918(97)80122-1David A. Sclar, Geneviève C. Tessier, Tracy L. Skaer, Randall F. Legg, Linda M. Robison, Neil L. Nemec Effect of pharmaceutical formulation of diltiazem on the utilization of medicaid and health maintenance organization services, Current Therapeutic Research 55, no.1010 (Oct 1994): 1136–1149.https://doi.org/10.1016/S0011-393X(05)80254-1 William J. Moore , and Robert J. Newman Drug Formulary Restrictions as a Cost-Containment Policy in Medicaid Programs, The Journal of Law and Economics 36, no.1, Part 11, Part 1 (Oct 2015): 71–97.https://doi.org/10.1086/467265Tracy L. Skaer, David A. Sclar, Linda M. Robison, Joanne K.H. Won, Daniel J. Markowski Effect of pharmaceutical formulation on health care expenditures for hypertension: A study of verapamil in a medicaid population, Current Therapeutic Research 53, no.33 (Mar 1993): 256–264.https://doi.org/10.1016/S0011-393X(05)80783-0Jeffrey S. Mccombs, Michael B. Nichol Pharmacy-Enforced Outpatient Drug Treatment Protocols: A Case Study of Medi-Cal Restrictions for Cefaclor, Annals of Pharmacotherapy 27, no.22 (Jun 2016): 155–161.https://doi.org/10.1177/106002809302700203Thomas J. Hoerger Market Failure, Information Imperfections, and Cost-Effectiveness Analysis, Drug Information Journal 26, no.44 (Aug 2016): 647–654.https://doi.org/10.1177/009286159202600425David Alexander Sclar, Tracy L. Skaer, Alfred Chin, Mark P. Okamoto, Mark A. Gill Utility of a transdermal delivery system for antihypertensive therapy. Part 1, The American Journal of Medicine 91, no.11 (Jul 1991): S50–S56.https://doi.org/10.1016/0002-9343(91)90063-4John G. Cullis Prescription Charges and Budgets: Towards an Assessment, Social Policy & Administration 24, no.22 (Aug 1990): 136–144.https://doi.org/10.1111/j.1467-9515.1990.tb00332.xG. Edward Miller, John Moeller Outpatient prescription drug prices and insurance coverage: An analysis by therapeutic drug class and user characteristics from the 1996 medical expenditure panel survey, (): 23–57.https://doi.org/10.1016/S0194-3960(01)14003-5